Cargando…

Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer.

The effect of anastrozole ('Arimidex', ZD1033), a new, selective, non-steroidal aromatase inhibitor on in vivo aromatisation and plasma oestrogen levels was evaluated in post-menopausal women with breast cancer. Twelve patients progressing after treatment with tamoxifen were randomised to...

Descripción completa

Detalles Bibliográficos
Autores principales: Geisler, J., King, N., Dowsett, M., Ottestad, L., Lundgren, S., Walton, P., Kormeset, P. O., Lønning, P. E.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1996
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2075919/
https://www.ncbi.nlm.nih.gov/pubmed/8883419
_version_ 1782138091304124416
author Geisler, J.
King, N.
Dowsett, M.
Ottestad, L.
Lundgren, S.
Walton, P.
Kormeset, P. O.
Lønning, P. E.
author_facet Geisler, J.
King, N.
Dowsett, M.
Ottestad, L.
Lundgren, S.
Walton, P.
Kormeset, P. O.
Lønning, P. E.
author_sort Geisler, J.
collection PubMed
description The effect of anastrozole ('Arimidex', ZD1033), a new, selective, non-steroidal aromatase inhibitor on in vivo aromatisation and plasma oestrogen levels was evaluated in post-menopausal women with breast cancer. Twelve patients progressing after treatment with tamoxifen were randomised to receive anastrozole 1 mg or 10 mg once daily for a 28 day period in a double-blinded crossover design. In vivo aromatisation and plasma oestrogen levels were determined before commencing treatment and at the end of each 4-week period. Treatment with anastrozole 1 and 10 mg reduced the percentage aromatisation from 2.25% to 0.074% and 0.043% (mean suppression of 96.7% and 98.1% from baseline) and suppressed plasma levels of oestrone, oestradiol and oestrone sulphate by > or = 86.5%, > or = 83.5% and > or = 93.5% respectively, irrespective of dose. Notably, several patients had their oestrone and oestradiol values suppressed beneath the sensitivity limit of the assays. In conclusion, anastrozole was found to be highly effective in inhibiting in vivo aromatisation with no difference in efficacy between the two drug doses. Contrary to previous studies on other aromatase inhibitors, this study revealed an internal consistency between the percentage aromatase inhibition and suppression of plasma oestrone sulphate.
format Text
id pubmed-2075919
institution National Center for Biotechnology Information
language English
publishDate 1996
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-20759192009-09-10 Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer. Geisler, J. King, N. Dowsett, M. Ottestad, L. Lundgren, S. Walton, P. Kormeset, P. O. Lønning, P. E. Br J Cancer Research Article The effect of anastrozole ('Arimidex', ZD1033), a new, selective, non-steroidal aromatase inhibitor on in vivo aromatisation and plasma oestrogen levels was evaluated in post-menopausal women with breast cancer. Twelve patients progressing after treatment with tamoxifen were randomised to receive anastrozole 1 mg or 10 mg once daily for a 28 day period in a double-blinded crossover design. In vivo aromatisation and plasma oestrogen levels were determined before commencing treatment and at the end of each 4-week period. Treatment with anastrozole 1 and 10 mg reduced the percentage aromatisation from 2.25% to 0.074% and 0.043% (mean suppression of 96.7% and 98.1% from baseline) and suppressed plasma levels of oestrone, oestradiol and oestrone sulphate by > or = 86.5%, > or = 83.5% and > or = 93.5% respectively, irrespective of dose. Notably, several patients had their oestrone and oestradiol values suppressed beneath the sensitivity limit of the assays. In conclusion, anastrozole was found to be highly effective in inhibiting in vivo aromatisation with no difference in efficacy between the two drug doses. Contrary to previous studies on other aromatase inhibitors, this study revealed an internal consistency between the percentage aromatase inhibition and suppression of plasma oestrone sulphate. Nature Publishing Group 1996-10 /pmc/articles/PMC2075919/ /pubmed/8883419 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Geisler, J.
King, N.
Dowsett, M.
Ottestad, L.
Lundgren, S.
Walton, P.
Kormeset, P. O.
Lønning, P. E.
Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer.
title Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer.
title_full Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer.
title_fullStr Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer.
title_full_unstemmed Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer.
title_short Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer.
title_sort influence of anastrozole (arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2075919/
https://www.ncbi.nlm.nih.gov/pubmed/8883419
work_keys_str_mv AT geislerj influenceofanastrozolearimidexaselectivenonsteroidalaromataseinhibitoroninvivoaromatisationandplasmaoestrogenlevelsinpostmenopausalwomenwithbreastcancer
AT kingn influenceofanastrozolearimidexaselectivenonsteroidalaromataseinhibitoroninvivoaromatisationandplasmaoestrogenlevelsinpostmenopausalwomenwithbreastcancer
AT dowsettm influenceofanastrozolearimidexaselectivenonsteroidalaromataseinhibitoroninvivoaromatisationandplasmaoestrogenlevelsinpostmenopausalwomenwithbreastcancer
AT ottestadl influenceofanastrozolearimidexaselectivenonsteroidalaromataseinhibitoroninvivoaromatisationandplasmaoestrogenlevelsinpostmenopausalwomenwithbreastcancer
AT lundgrens influenceofanastrozolearimidexaselectivenonsteroidalaromataseinhibitoroninvivoaromatisationandplasmaoestrogenlevelsinpostmenopausalwomenwithbreastcancer
AT waltonp influenceofanastrozolearimidexaselectivenonsteroidalaromataseinhibitoroninvivoaromatisationandplasmaoestrogenlevelsinpostmenopausalwomenwithbreastcancer
AT kormesetpo influenceofanastrozolearimidexaselectivenonsteroidalaromataseinhibitoroninvivoaromatisationandplasmaoestrogenlevelsinpostmenopausalwomenwithbreastcancer
AT lønningpe influenceofanastrozolearimidexaselectivenonsteroidalaromataseinhibitoroninvivoaromatisationandplasmaoestrogenlevelsinpostmenopausalwomenwithbreastcancer